New drug development in metastatic prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 4, 2008, Pages 430-437

  Armstrong, Andrew J ^a   George, Daniel J ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Castration resistant; Chemotherapy; Drug development; HDAC inhibitors; Hormone refractory; Immunotherapy; mTOR; Novel agents; Prostate cancer; Vitamin D

Indexed keywords

AP 23573; ATRASENTAN; BEVACIZUMAB; BIOLOGICAL MARKER; DOCETAXEL; EVEROLIMUS; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; LAPATINIB; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDAREX; PANOBINOSTAT; PREDNISONE; SIPULEUCEL T; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TRASTUZUMAB; VATALANIB; VORINOSTAT; ZK 22584;

ANGIOGENESIS; CASTRATION; CASTRATION RESISTANT METASTATIC PROSTATE CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; METASTASIS; MOLECULAR DYNAMICS; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANDROGEN ANTAGONISTS; ANGIOGENESIS INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 45849119070     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.11.006     Document Type: Review

References (63)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2007. CA Cancer J Clin 57 (2007) 43-66
2. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
3. Armstrong A.J., and Carducci M.A. Novel therapeutic approaches to advanced prostate cancer. Clin Adv Hematol Oncol 3 (2005) 271-282
4. Petrylak D.P., Ankerst D.P., Jiang C.S., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98 (2006) 516-521
5. Armstrong A.J., Ou Yang Y., Garrett-Mayer E.S., et al. Prostate specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25 (2007) 3965-3970
6. Bubley G.J., Carducci M.A., Dahut W., et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461-3467
7. Carducci M.A., Gilbert J., Bowling M.K., et al. A Phase I clinical and pharmacologic evaluation of sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7 (2001) 3047-3055
8. Armstrong A.J., Garrett-Mayer E.S., de Wit R., et al. Limitations of the current progression-free survival (PFS) definition in hormone-refractory prostate cancer (HRPC): Benefit associated with continuation of docetaxel beyond TAX327 protocol-defined progression. Proceedings of the American Society Clinical Oncology Prostate Cancer Symposium, Orlando, FL, February 22-24, 2007 (2007), American Society of Clinical Oncology [Abstract 223]
9. Sternberg C.N. Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int 96 (2005) 990-994
10. Berthold D.R., Pond G., De Wit R., et al. Association of pain and quality of life response with PSA response and survival of patients with metastatic hormone refractory prostate cancer treated with docetaxel or mitoxantrone in the TAX327 study. J Clin Oncol 24 18S (2006) 4516 [Abstract]
11. Jaffe C.C. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 10 (2006) 3245-3251
12. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
13. Friedlin B., and Simon R. Evaluation of randomized discontinuation design. J Clin Oncol 23 (2005) 5094-5098
14. Simon R., and Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 10 (2004) 6759-6763
15. Tomlins S.A., Mehra R., Rhodes D.R., et al. Integrated molecular concept modeling of prostate cancer progression. Nature Genet 39 (2007) 41-51
16. Weidner N., Carroll P., Flax J., et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143 (1993) 401-409
17. Borre M., Offersen B., Nerstom B., et al. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78 (1998) 940-944
18. George D., Halabi S., Shepard T., et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7 (2001) 1932-1936
19. Picus J., Halabi S., Rini B., et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proc Am Soc Clin Oncol 22 (2003) 393 [Abstract] 1578
20. Bartlett J.B., Dredge K., and Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Rev Cancer 4 (2004) 314-322
21. Figg W.D., Dahut W., Duray P., et al. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in androgen-independent prostate cancer. Clin Cancer Res 7 (2001) 1888-1893
22. Mathew P., Thall P.F., Jones D., et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular Phase I trial in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 3323-3329
23. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med 356 (2007) 125-134
24. Morabito A., De Maio E., Di Maio M., et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. Oncologist 11 (2006) 753-764
25. Wu S., Posadas E., Scripture C., et al. BAY 43-9006 (sorafenib) can lead to improvement of bone lesions in metastatic androgen-independent prostate cancer despite rises in serum PSA levels. Proceedings of the Prostate Cancer Symposium, Orlando, FL, February 24-26, 2006 (2006), American Society of Clinical Oncology [Abstract 259]
26. Wood J., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor vascular endothelial growth factor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178-2189
27. George D., Oh W., Gilligan T., et al. Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC). J Clin Oncol 22 (2004) 14s [Abstract] 4689
28. Weinstein I.B. Addiction to oncogenes: The Achilles heel of cancer. Science 297 (2002) 102-104
29. McMenamin M.E., Soung P., Perera S., et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59 (1999) 4291-4296
30. Wu X., Senechal K., Neshat M.S., et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/akt pathway. Proc Natl Acad Sci USA 95 (1998) 15587-15591
31. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase-akt pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
32. Bjornsti M., and Houghton P.J. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 4 (2004) 335-348
33. Lerut E., Roskams T., Goossens T., et al. Molecular pharmacodynamic evaluation of dose and schedule of RAD001 in patients with operable prostate cancer. J Clin Oncol 23 (2005) 3071
34. Thomas G., Speicher L., Reiter R., et al. Demonstration that temsirolimus preferentially inhibits the mTOR pathway in the tumors of prostate cancer patients with PTEN deficiencies. Proceedings of AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA, November 14-18, 2005 (2005) EORTC-AACR-NCI, [Abstract C131]
35. Grunwald V., DeGraffenried L., Russel D., et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62 (2002) 6141-6145
36. Gregory C., Whang Y., McCall W., et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11 (2005) 1704-1712
37. Canil C., Moore M., Winquist E., et al. Randomized Phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23 (2005) 455-460
38. Ziada A., Barqawi A., Glode L., et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer Phase II trial. Prostate 60 (2004) 332-337
39. Liu Y., Majmunder S., McCall W., et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 65 (2005) 3404-3409
40. Sergina N.V., Rausch M., Wang D., et al. Escape from Her-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445 (2007) 437-441
41. Mapara M.Y., and Sykes M. Tolerance and cancer: Mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22 (2004) 1136-1151
42. Webster W., Small E., Rini B., et al. Prostate Cancer Immunology: Biology, therapeutics, and challenges. J Clin Oncol 23 (2005) 8262-8269
43. Small E., Schellhammer P., Higano C., et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 (2006) 3089-3094
44. Small E., Higano C., Smith D., et al. A Phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 23 (2004) 4565
45. Small E., Higano C., Smith D., et al. Analysis of prognostic variables in Phase II trials of GVAX Vaccine for prostate cancer in metastatic hormone refractory prostate cancer. American Society of Clinical Oncology Prostate Cancer Symposium, Orlando, FL, February 24-26, 2006 (2006), American Society of Clinical Oncology [Abstract 254]
46. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: A review (United States). Cancer Causes Control 16 (2005) 83-95
47. Peehl D.M., Skowronski R.J., Leung G.K., et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54 (1994) 805-810
48. Vijayakumar S, Mehta RR, Boerner PS. Clinical trials involving vitamin D analogs in prostate cancer. Cancer J 1005;11:362-73.
49. Beer T., Ryan C., Venner P., et al. Interim results for ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). J Clin Oncol 23 (2005) 4516
50. Novacea, Inc. Novacea halts ASCENT-2 trial in advanced prostate cancer (Press Release 11/5/07). http://www.novacea.com/610.asp?id=136&nav=news Accessed December 9, 2007
51. Kelly W.K., O'Connor O.A., Krug L.M., et al. A Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 (2005) 3923-3931
52. Carducci M.A., Gilbert J., Bowling M.K., et al. A Phase I clinical and pharmacologic evaluation of sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7 (2001) 3047-3055
53. Armstrong A.J., and Carducci M.A. Chemotherapy for advanced prostate cancer. In: Kirby R.S., Partin A., Feneley M., et al. (Eds). Principles and Practice of Prostate Cancer. 1st ed. (2005), Martin Dunitz, London, UK 989-1004
54. Berthold D.R., Sternberg C.N., and Tannock I.F. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 23 (2005) 8247-8252
55. Lin A., Rosenberg V., Weinberg W., et al. Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients treated with subsequent chemotherapy (ixabepilone or mitoxantrone/prednisone). J Clin Oncol 24 (2006) 4558
56. Sternberg C., Whelan P., Hetherington J., et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68 (2005) 2-9
57. Jackson J.R., Patrick D.R., Dar M.M., et al. Targeted anti-mitotic therapies: Can we improve on tubulin agents?. Nat Rev Cancer 7 (2007) 107-117
58. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39
59. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
60. Ryan C.J., Halabi S., Ou S.S., et al. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a cancer and leukemia group B study. Clin Cancer Res 13 (2007) 2030-2037
61. Attard G., Yap T.A., Reid A.H., et al. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor. J Clin Oncol 25 suppl 18 (2007) 5063 [Abstract]
62. O'Donnell A., Judson I., Dowsett M., et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90 (2004) 2317-2325
63. Ryan C.J., Rosenberg J., Lin A., et al. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-lyase inhibitor in androgen-independent prostate cancer (AiPC). J Clin Oncol 25 suppl 18 (2007) 5064 [Abstract]